Please login to the form below

Not currently logged in
Email:
Password:

Takeda remains robust

Japanese firm posts strong net income but falling revenues for Q1 as the strength of the yen takes its toll

Takeda has posted a strong net income of 112.6bn yen ($1.2bn) for the first quarter, up from 2.5bn yen ($26m) in the same reporting period last year and some 30.1bn yen above analysts' expectations.

In the three months ended June 30, the Japanese company saw sales of a number of its leading products fall due to the strength of the yen. Revenue from type 2 diabetes treatment Actos fell 6.6 per cent to 96.4bn yen ($1bn), while sales of Takepron dropped 2.6 per cent to 70.5bn yen ($736m) and Blopress revenues fell 5.5 per cent to 56.6bn yen ($591m). Net sales for the period fell 4.5 per cent (17.9bn yen) to 379bn yen ($4bn).

Daiichi suffers loss
Japan's third-largest manufacturer, Daiichi Sankyo has reported a loss of 6.4bn yen ($67m) in the three months to June 30 compared with a net income of 25.1bn yen ($263m) for the first quarter of 2008.

The company's quarterly sales were up 11.5 per cent to 227.1bn yen ($2.4bn), of which 29.6bn yen ($310m) came from Ranbaxy of which Daiichi Sankyo is a majority shareholder.

Ordinary income has been upwardly revised to 37bn yen ($389m) from 20bn yen ($210m) and net income has been upwardly revised to 11bn yen ($115m), up 3bn yen ($31.5m). The earnings forecast for the full fiscal year remain unchanged.

3rd August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics